モノクローナル抗体発見プラットフォームの世界市場レポート2026-2032

QY Research > レポート一覧 > メディカルケア > モノクローナル抗体発見プラットフォームの世界市場レポート2026-2032

英文タイトル： Global Monoclonal Antibody Discovery Platform Market Research Report 2026

レポートID：1814334
発表時期：2026-08-16
訪問回数：142
ページ数：123
レポート形式：PDF
レポート言語：英語、日本語
グラフ数：134
レポートカテゴリ：メディカルケア

販売価格（消費税別）

個人版
詳細
マルチユーザー版
詳細
企業版
詳細

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.50円。
※米ドル表示価格+10％消費税。

英語版

日本語版

英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.50円。
※米ドル表示価格+10％消費税。

お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合，注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。但し、日本語版が必要な場合は、受注後8～10営業日となります。お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

概要

世界のモノクローナル抗体発見プラットフォーム市場は、2025年に331百万米ドルと算定されており、2026年には358百万米ドルとなる見通しです。2026年から2032年の期間においては年平均成長率（CAGR）7.9%で推移し、2032年には565百万米ドルに達すると予測されています。

モノクローナル抗体発見プラットフォームの世界市場レポート2026-2032

主要市場統計

予測期間

2025年~2032年

2025年の評価

331

2026年の予測

358

2032年の予測

565

CAGR(2025~2032)年

7.9%

本レポートは、モノクローナル抗体発見プラットフォームメーカー、新規参入企業、および業界バリューチェーン全体の企業に対し、市場全体およびサブセグメント別の収益、生産量、平均価格に関する情報を、企業別、タイプ別、用途別、地域別に提供します。
世界のモノクローナル抗体発見プラットフォーム市場について、定量的・定性的分析を交えた包括的な概観を提供し、企業関係者が成長戦略の策定、競争環境の評価、現行市場における自社の位置付けの分析、モノクローナル抗体発見プラットフォームに関する情報に基づいたビジネス判断を行うことを支援します。モノクローナル抗体発見プラットフォーム市場の規模、推定値及び予測値の観点から提示し、2025年を基準年として、2021年から2032年までの過去データ及び予測データを収録しております。

報告対象範囲
売上高・数量予測、企業シェア、競争環境、成長要因および市場トレンド

市場セグメンテーション
企業一覧
AbCellera Biologics Inc. (CA)
Twist Bioscience Corporation (US)
Adimab LLC (US)
Alloy Therapeutics, Inc. (US)
Biocytogen Pharmaceuticals Co., Ltd. (CN)
WuXi Biologics (CN)
Charles River Laboratories International, Inc. (US)
Sartorius AG (DE)
BioNTech SE (DE)
Grifols, S.A. (ES)
Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN)
Harbour BioMed (CN)
3SBio Inc. (CN)
Lepu Biopharma Co., Ltd. (CN)
Creative Biolabs (US)
Integral Molecular, Inc. (US)
AvantGen, Inc. (US)
ProteoGenix (FR)

タイプ別
Hybridoma
Single B Cell
Phage and Yeast Display
Transgenic Animal
AI De Novo Design

用途別
Therapeutic Antibody Discovery
Diagnostic Antibodies
Research Reagents
Veterinary Biologics
Other

製品カテゴリー

市場セグメント
Below 10,000 cells per run
10,000–100,000 cells per run
Above 100,000 cells per run

地域別
北米（アメリカ、カナダ、メキシコ）
欧州（ドイツ、フランス、イギリス、イタリアなど）
アジア太平洋（中国、日本、韓国、東南アジア、インドなど）
南米（ブラジルなど）
中東・アフリカ（トルコ、GCC諸国、アフリカなど）
本レポートは、世界のモノクローナル抗体発見プラットフォーム市場を包括的にセグメント化しております。地域別市場規模、タイプ別、用途別、企業別の市場規模も提供されます。より深い洞察を得るため、競争環境、主要競合他社、それぞれの市場順位をプロファイリングし、技術動向や新製品開発についても論じております。

本レポートの構成
第1章：モノクローナル抗体発見プラットフォームの定義および調査範囲を明確化し、市場セグメント（タイプ別、用途別など）の概要を提示します。各セグメントの市場規模と将来の成長可能性を網羅し、現在の市場状況の概要を提供するとともに、短期・中期・長期の発展トレンドを分析します
第2章：モノクローナル抗体発見プラットフォームメーカーの競争環境について、価格、生産量、価値ベースの市場シェア、最新の開発計画、合併・買収情報を含め詳細に分析します
第3章：モノクローナル抗体発見プラットフォームの生産量／生産高および価値を地域・国別に検証し、今後6年間の各地域の市場規模と成長可能性について定量的な評価を提供します
第4章：地域および国レベルでのモノクローナル抗体発見プラットフォームの消費動向を分析します。各地域および主要国における市場規模と成長可能性を定量化し、市場開発状況、見通し、対応可能な市場規模、国内生産量を概説します
第5章：モノクローナル抗体発見プラットフォームに基づくタイプ別市場セグメントの構造を整理し、各セグメントの市場規模と成長ポテンシャルを明確化することで、企業・投資家によるブルーオーシャン機会の発見を支援します
第6章：用途別にモノクローナル抗体発見プラットフォームの市場セグメントを整理し、各分野の市場規模、成長ポテンシャル、需要拡大余地を提示することで、下流市場における有望な参入機会や競争優位の確立に向けた判断材料を提供します
第7章：モノクローナル抗体発見プラットフォームの主要プレイヤーを分析し、主要企業の基本情報（製品生産量／生産高、価値、価格、粗利益率、製品ポートフォリオ／新製品導入、最近の動向）を詳細に説明します
第8章：モノクローナル抗体発見プラットフォームの上流および下流セグメントを含む業界バリューチェーンをレビューします
第9章：モノクローナル抗体発見プラットフォーム市場の動向と最新トレンドについて議論します。これには、メーカーにとっての推進要因、制約要因、課題、リスク、米国関税、関連政策分析が含まれます
第10章：主な調査結果と結論をまとめます
第11章：付録

Description

The global Monoclonal Antibody Discovery Platform market was valued at US$ 331 million in 2025 and is anticipated to reach US$ 565 million by 2032, at a CAGR of 7.9% from 2026 to 2032.

A monoclonal antibody drug discovery platform is an integrated technology and service system used to generate, isolate, screen and characterize monoclonal antibodies against therapeutic targets. The study object covers immunization and transgenic animal systems, hybridoma, single-B-cell, phage and yeast display, microfluidic and optofluidic screening, sequencing, recombinant expression and functional validation, enabling selection of leads for therapeutic antibody and related biologic development.

Key Findings
Global monoclonal antibody discovery platform project sales reached approximately 9,200 projects in 2025
The global average selling price was approximately US$36,000 per project in 2025
The global industry capacity utilization rate was approximately 72% during 2025
The global industry-wide average gross margin was approximately 51% during 2025
Cost structure was biological models and libraries 21%, scientific labor 25%, screening instruments 18%, sequencing and data 13%, validation 11%, and sales and administration 12%
Market Trends
Single-cell, microfluidic and AI-enabled discovery is shortening cycle time while preserving native heavy-light pairing and expanding sequence diversity. Product development is increasingly evaluated through lifecycle reliability, process repeatability, digital traceability and the ability to integrate with customers’ existing workflows. Buyers are placing more weight on total cost of ownership and validation evidence, which is encouraging suppliers to combine standardized platforms with configurable modules and application-specific engineering.
Market Dynamics
Platform demand follows biotechnology funding, target novelty and the need to generate differentiated binders for complex or weakly immunogenic antigens. Demand is therefore shaped by a balance between performance improvement, qualification cost, supply assurance and customers’ willingness to redesign established processes. The market favors suppliers that can shorten validation cycles, support scale-up and maintain consistent quality across regions while preserving enough flexibility for customer-specific specifications.
Drivers
Expanding antibody, bispecific, antibody-drug conjugate and immuno-oncology pipelines support outsourcing and platform licensing. Replacement of labor-intensive or lower-reliability solutions is accelerating where customers can quantify gains in yield, uptime, safety or product quality. Broader capital investment in the principal downstream industries also supports demand, while stricter quality systems and traceability requirements raise the value of products and services with documented performance.
Restraints
High program costs, variable biological success rates and downstream developability failures limit the conversion of campaigns into clinical assets. Adoption can be delayed by qualification expense, long procurement cycles and the cost of changing validated production routes. Smaller customers may postpone purchases when utilization is uncertain, while fragmented technical standards and uneven after-sales capability make direct comparison difficult and increase the perceived switching risk.
Opportunities
Difficult-target discovery, species-cross-reactive antibodies, multispecific building blocks and data-rich partnerships offer premium opportunities. Suppliers can capture additional value through application engineering, modular customization, local technical support and data-enabled service packages. High-growth opportunities are concentrated in customers that are expanding capacity, localizing critical supply chains or moving from laboratory and pilot use to repeatable commercial production.
Challenges
Platforms must differentiate true biological quality from screening volume and manage ownership of sequences, datasets and downstream economics. Competitive pressure may compress prices in standardized segments even as customers demand higher reliability and faster delivery. Companies must manage qualification failures, intellectual-property exposure, specialized talent shortages and fluctuations in key material or equipment costs without weakening product consistency or customer support.
Industry Chain Analysis
Upstream elements include target biology, antigens, animal models, display libraries, single-cell instruments, sequencing, expression and assay reagents. The midstream combines product design, process development, manufacturing or service execution, quality control and documentation. Downstream value is realized when the offering improves customers’ throughput, reliability, compliance or end-product performance, making supplier qualification, co-development and technical support important links across the chain.
Value Chain Analysis
Value concentrates in proprietary biological systems, high-quality screening, paired sequence data, functional assays and the probability of producing developable leads. Value creation is concentrated in proprietary know-how, process stability, yield management, validation data and the ability to solve application-specific problems. Basic materials and routine processing account for a smaller share of differentiated value, while engineering, quality assurance, customer qualification and long-term service strengthen retention and support premium pricing.
Segment Insights
Single-B-cell and transgenic-animal approaches lead high-value programs, while display libraries remain scalable for large diversity and difficult targets. The most attractive segment is not necessarily the highest-volume category; it is generally the segment where technical complexity, qualification barriers and failure costs are greatest. Standard products remain important for scale and channel coverage, whereas higher-specification variants generate stronger service intensity, longer customer relationships and more defensible margins.
Downstream Market Opportunities
Biopharmaceutical companies, virtual biotechnology firms and academic translational centers are principal users, with licensing partners extending value downstream. Near-term opportunities are strongest among customers adding new production lines, upgrading legacy equipment or materials, and entering applications with stricter reliability requirements. Suppliers that can provide samples, pilot validation, design-in support and responsive local service are better positioned to convert technical interest into recurring procurement.
Regional Insights
North America has the largest platform ecosystem, Europe remains strong in specialist biology, and China is rapidly integrating discovery with development and manufacturing. Regional competition differs by customer concentration, certification practice, supply-chain localization and service expectations. Mature markets emphasize validated performance and lifecycle support, while faster-growing Asian markets combine large capacity additions with stronger demand for local delivery, cost control and rapid customization.
Competitive Landscape Analysis
Competition combines proprietary mouse strains, display diversity, single-cell throughput, AI datasets, deal structures and downstream development capability. Competition is based less on nominal specification lists than on verified performance, installed references, delivery reliability and application support. Global leaders retain advantages in brand, qualification data and international service, while regional specialists compete through faster customization, lower operating cost and closer engineering collaboration. No market-share ranking is stated where comparable audited evidence is unavailable.

Report Scope
This report delivers a comprehensive overview of the global Monoclonal Antibody Discovery Platform market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Monoclonal Antibody Discovery Platform. The Monoclonal Antibody Discovery Platform market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Monoclonal Antibody Discovery Platform market comprehensively. Regional market sizes by Discovery Source, by Application, by Screening Technology, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Monoclonal Antibody Discovery Platform manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Discovery Source, by Application, and by region.

Market Segmentation
By Company
AbCellera Biologics Inc. (CA)
Twist Bioscience Corporation (US)
Adimab LLC (US)
Alloy Therapeutics, Inc. (US)
Biocytogen Pharmaceuticals Co., Ltd. (CN)
WuXi Biologics (CN)
Charles River Laboratories International, Inc. (US)
Sartorius AG (DE)
BioNTech SE (DE)
Grifols, S.A. (ES)
Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN)
Harbour BioMed (CN)
3SBio Inc. (CN)
Lepu Biopharma Co., Ltd. (CN)
Creative Biolabs (US)
Integral Molecular, Inc. (US)
AvantGen, Inc. (US)
ProteoGenix (FR)

Segment by Discovery Source
Hybridoma
Single B Cell
Phage and Yeast Display
Transgenic Animal
AI De Novo Design

Segment by Screening Technology
FACS
Microfluidics
Optofluidics
High-Content Screening

Segment by Screening Throughput
Below 10,000 cells per run
10,000–100,000 cells per run
Above 100,000 cells per run

Segment by Application
Therapeutic Antibody Discovery
Diagnostic Antibodies
Research Reagents
Veterinary Biologics
Other

By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA

Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Discovery Source, by Application, by Screening Technology, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Monoclonal Antibody Discovery Platform companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Discovery Source, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Discovery Source
1.2.1 Global Monoclonal Antibody Discovery Platform Market Size Growth Rate by Discovery Source: 2021 vs 2025 vs 2032
1.2.2 Hybridoma
1.2.3 Single B Cell
1.2.4 Phage and Yeast Display
1.2.5 Transgenic Animal
1.2.6 AI De Novo Design
1.3 Market by Screening Technology
1.3.1 Global Monoclonal Antibody Discovery Platform Market Size Growth Rate by Screening Technology: 2021 vs 2025 vs 2032
1.3.2 FACS
1.3.3 Microfluidics
1.3.4 Optofluidics
1.3.5 High-Content Screening
1.4 Market by Screening Throughput
1.4.1 Global Monoclonal Antibody Discovery Platform Market Size Growth Rate by Screening Throughput: 2021 vs 2025 vs 2032
1.4.2 Below 10,000 cells per run
1.4.3 10,000–100,000 cells per run
1.4.4 Above 100,000 cells per run
1.5 Market by Application
1.5.1 Global Monoclonal Antibody Discovery Platform Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Therapeutic Antibody Discovery
1.5.3 Diagnostic Antibodies
1.5.4 Research Reagents
1.5.5 Veterinary Biologics
1.5.6 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Global Growth Trends
2.1 Global Monoclonal Antibody Discovery Platform Market Perspective (2021–2032)
2.2 Global Monoclonal Antibody Discovery Platform Growth Trends by Region
2.2.1 Global Monoclonal Antibody Discovery Platform Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Monoclonal Antibody Discovery Platform Historic Market Size by Region (2021–2026)
2.2.3 Monoclonal Antibody Discovery Platform Forecasted Market Size by Region (2027–2032)
2.3 Monoclonal Antibody Discovery Platform Market Dynamics
2.3.1 Monoclonal Antibody Discovery Platform Industry Trends
2.3.2 Monoclonal Antibody Discovery Platform Market Drivers
2.3.3 Monoclonal Antibody Discovery Platform Market Challenges
2.3.4 Monoclonal Antibody Discovery Platform Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Monoclonal Antibody Discovery Platform Players by Revenue
3.1.1 Global Top Monoclonal Antibody Discovery Platform Players by Revenue (2021–2026)
3.1.2 Global Monoclonal Antibody Discovery Platform Revenue Market Share by Players (2021–2026)
3.2 Global Top Monoclonal Antibody Discovery Platform Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Monoclonal Antibody Discovery Platform Revenue
3.4 Global Monoclonal Antibody Discovery Platform Market Concentration Ratio
3.4.1 Global Monoclonal Antibody Discovery Platform Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal Antibody Discovery Platform Revenue in 2025
3.5 Global Key Players of Monoclonal Antibody Discovery Platform Head Offices and Areas Served
3.6 Global Key Players of Monoclonal Antibody Discovery Platform, Products and Applications
3.7 Global Key Players of Monoclonal Antibody Discovery Platform, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans

4 Monoclonal Antibody Discovery Platform Breakdown Data by Discovery Source
4.1 Global Monoclonal Antibody Discovery Platform Historic Market Size by Discovery Source (2021–2026)
4.2 Global Monoclonal Antibody Discovery Platform Forecasted Market Size by Discovery Source (2027–2032)

5 Monoclonal Antibody Discovery Platform Breakdown Data by Application
5.1 Global Monoclonal Antibody Discovery Platform Historic Market Size by Application (2021–2026)
5.2 Global Monoclonal Antibody Discovery Platform Forecasted Market Size by Application (2027–2032)

6 North America
6.1 North America Monoclonal Antibody Discovery Platform Market Size (2021–2032)
6.2 North America Monoclonal Antibody Discovery Platform Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Monoclonal Antibody Discovery Platform Market Size by Country (2021–2026)
6.4 North America Monoclonal Antibody Discovery Platform Market Size by Country (2027–2032)
6.5 United States
6.6 Canada

7 Europe
7.1 Europe Monoclonal Antibody Discovery Platform Market Size (2021–2032)
7.2 Europe Monoclonal Antibody Discovery Platform Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Monoclonal Antibody Discovery Platform Market Size by Country (2021–2026)
7.4 Europe Monoclonal Antibody Discovery Platform Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland

8 Asia-Pacific
8.1 Asia-Pacific Monoclonal Antibody Discovery Platform Market Size (2021–2032)
8.2 Asia-Pacific Monoclonal Antibody Discovery Platform Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Monoclonal Antibody Discovery Platform Market Size by Region (2021–2026)
8.4 Asia-Pacific Monoclonal Antibody Discovery Platform Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand

9 Latin America
9.1 Latin America Monoclonal Antibody Discovery Platform Market Size (2021–2032)
9.2 Latin America Monoclonal Antibody Discovery Platform Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Monoclonal Antibody Discovery Platform Market Size by Country (2021–2026)
9.4 Latin America Monoclonal Antibody Discovery Platform Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Monoclonal Antibody Discovery Platform Market Size (2021–2032)
10.2 Middle East & Africa Monoclonal Antibody Discovery Platform Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Monoclonal Antibody Discovery Platform Market Size by Country (2021–2026)
10.4 Middle East & Africa Monoclonal Antibody Discovery Platform Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE

11 Key Players Profiles
11.1 AbCellera Biologics Inc. (CA)
11.1.1 AbCellera Biologics Inc. (CA) Company Details
11.1.2 AbCellera Biologics Inc. (CA) Business Overview
11.1.3 AbCellera Biologics Inc. (CA) Monoclonal Antibody Discovery Platform Introduction
11.1.4 AbCellera Biologics Inc. (CA) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.1.5 AbCellera Biologics Inc. (CA) Recent Development
11.2 Twist Bioscience Corporation (US)
11.2.1 Twist Bioscience Corporation (US) Company Details
11.2.2 Twist Bioscience Corporation (US) Business Overview
11.2.3 Twist Bioscience Corporation (US) Monoclonal Antibody Discovery Platform Introduction
11.2.4 Twist Bioscience Corporation (US) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.2.5 Twist Bioscience Corporation (US) Recent Development
11.3 Adimab LLC (US)
11.3.1 Adimab LLC (US) Company Details
11.3.2 Adimab LLC (US) Business Overview
11.3.3 Adimab LLC (US) Monoclonal Antibody Discovery Platform Introduction
11.3.4 Adimab LLC (US) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.3.5 Adimab LLC (US) Recent Development
11.4 Alloy Therapeutics, Inc. (US)
11.4.1 Alloy Therapeutics, Inc. (US) Company Details
11.4.2 Alloy Therapeutics, Inc. (US) Business Overview
11.4.3 Alloy Therapeutics, Inc. (US) Monoclonal Antibody Discovery Platform Introduction
11.4.4 Alloy Therapeutics, Inc. (US) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.4.5 Alloy Therapeutics, Inc. (US) Recent Development
11.5 Biocytogen Pharmaceuticals Co., Ltd. (CN)
11.5.1 Biocytogen Pharmaceuticals Co., Ltd. (CN) Company Details
11.5.2 Biocytogen Pharmaceuticals Co., Ltd. (CN) Business Overview
11.5.3 Biocytogen Pharmaceuticals Co., Ltd. (CN) Monoclonal Antibody Discovery Platform Introduction
11.5.4 Biocytogen Pharmaceuticals Co., Ltd. (CN) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.5.5 Biocytogen Pharmaceuticals Co., Ltd. (CN) Recent Development
11.6 WuXi Biologics (CN)
11.6.1 WuXi Biologics (CN) Company Details
11.6.2 WuXi Biologics (CN) Business Overview
11.6.3 WuXi Biologics (CN) Monoclonal Antibody Discovery Platform Introduction
11.6.4 WuXi Biologics (CN) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.6.5 WuXi Biologics (CN) Recent Development
11.7 Charles River Laboratories International, Inc. (US)
11.7.1 Charles River Laboratories International, Inc. (US) Company Details
11.7.2 Charles River Laboratories International, Inc. (US) Business Overview
11.7.3 Charles River Laboratories International, Inc. (US) Monoclonal Antibody Discovery Platform Introduction
11.7.4 Charles River Laboratories International, Inc. (US) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.7.5 Charles River Laboratories International, Inc. (US) Recent Development
11.8 Sartorius AG (DE)
11.8.1 Sartorius AG (DE) Company Details
11.8.2 Sartorius AG (DE) Business Overview
11.8.3 Sartorius AG (DE) Monoclonal Antibody Discovery Platform Introduction
11.8.4 Sartorius AG (DE) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.8.5 Sartorius AG (DE) Recent Development
11.9 BioNTech SE (DE)
11.9.1 BioNTech SE (DE) Company Details
11.9.2 BioNTech SE (DE) Business Overview
11.9.3 BioNTech SE (DE) Monoclonal Antibody Discovery Platform Introduction
11.9.4 BioNTech SE (DE) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.9.5 BioNTech SE (DE) Recent Development
11.10 Grifols, S.A. (ES)
11.10.1 Grifols, S.A. (ES) Company Details
11.10.2 Grifols, S.A. (ES) Business Overview
11.10.3 Grifols, S.A. (ES) Monoclonal Antibody Discovery Platform Introduction
11.10.4 Grifols, S.A. (ES) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.10.5 Grifols, S.A. (ES) Recent Development
11.11 Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN)
11.11.1 Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Company Details
11.11.2 Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Business Overview
11.11.3 Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Monoclonal Antibody Discovery Platform Introduction
11.11.4 Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.11.5 Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Recent Development
11.12 Harbour BioMed (CN)
11.12.1 Harbour BioMed (CN) Company Details
11.12.2 Harbour BioMed (CN) Business Overview
11.12.3 Harbour BioMed (CN) Monoclonal Antibody Discovery Platform Introduction
11.12.4 Harbour BioMed (CN) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.12.5 Harbour BioMed (CN) Recent Development
11.13 3SBio Inc. (CN)
11.13.1 3SBio Inc. (CN) Company Details
11.13.2 3SBio Inc. (CN) Business Overview
11.13.3 3SBio Inc. (CN) Monoclonal Antibody Discovery Platform Introduction
11.13.4 3SBio Inc. (CN) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.13.5 3SBio Inc. (CN) Recent Development
11.14 Lepu Biopharma Co., Ltd. (CN)
11.14.1 Lepu Biopharma Co., Ltd. (CN) Company Details
11.14.2 Lepu Biopharma Co., Ltd. (CN) Business Overview
11.14.3 Lepu Biopharma Co., Ltd. (CN) Monoclonal Antibody Discovery Platform Introduction
11.14.4 Lepu Biopharma Co., Ltd. (CN) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.14.5 Lepu Biopharma Co., Ltd. (CN) Recent Development
11.15 Creative Biolabs (US)
11.15.1 Creative Biolabs (US) Company Details
11.15.2 Creative Biolabs (US) Business Overview
11.15.3 Creative Biolabs (US) Monoclonal Antibody Discovery Platform Introduction
11.15.4 Creative Biolabs (US) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.15.5 Creative Biolabs (US) Recent Development
11.16 Integral Molecular, Inc. (US)
11.16.1 Integral Molecular, Inc. (US) Company Details
11.16.2 Integral Molecular, Inc. (US) Business Overview
11.16.3 Integral Molecular, Inc. (US) Monoclonal Antibody Discovery Platform Introduction
11.16.4 Integral Molecular, Inc. (US) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.16.5 Integral Molecular, Inc. (US) Recent Development
11.17 AvantGen, Inc. (US)
11.17.1 AvantGen, Inc. (US) Company Details
11.17.2 AvantGen, Inc. (US) Business Overview
11.17.3 AvantGen, Inc. (US) Monoclonal Antibody Discovery Platform Introduction
11.17.4 AvantGen, Inc. (US) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.17.5 AvantGen, Inc. (US) Recent Development
11.18 ProteoGenix (FR)
11.18.1 ProteoGenix (FR) Company Details
11.18.2 ProteoGenix (FR) Business Overview
11.18.3 ProteoGenix (FR) Monoclonal Antibody Discovery Platform Introduction
11.18.4 ProteoGenix (FR) Revenue in Monoclonal Antibody Discovery Platform Business (2021–2026)
11.18.5 ProteoGenix (FR) Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Monoclonal Antibody Discovery Platform Market Size Growth Rate by Discovery Source (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Hybridoma
 Table 3. Key Players of Single B Cell
 Table 4. Key Players of Phage and Yeast Display
 Table 5. Key Players of Transgenic Animal
 Table 6. Key Players of AI De Novo Design
 Table 7. Global Monoclonal Antibody Discovery Platform Market Size Growth Rate by Screening Technology (US$ Million): 2021 vs 2025 vs 2032
 Table 8. Key Players of FACS
 Table 9. Key Players of Microfluidics
 Table 10. Key Players of Optofluidics
 Table 11. Key Players of High-Content Screening
 Table 12. Global Monoclonal Antibody Discovery Platform Market Size Growth Rate by Screening Throughput (US$ Million): 2021 vs 2025 vs 2032
 Table 13. Key Players of Below 10,000 cells per run
 Table 14. Key Players of 10,000–100,000 cells per run
 Table 15. Key Players of Above 100,000 cells per run
 Table 16. Global Monoclonal Antibody Discovery Platform Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Monoclonal Antibody Discovery Platform Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 18. Global Monoclonal Antibody Discovery Platform Market Size by Region (US$ Million), 2021–2026
 Table 19. Global Monoclonal Antibody Discovery Platform Market Share by Region (2021–2026)
 Table 20. Global Monoclonal Antibody Discovery Platform Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 21. Global Monoclonal Antibody Discovery Platform Market Share by Region (2027–2032)
 Table 22. Monoclonal Antibody Discovery Platform Market Trends
 Table 23. Monoclonal Antibody Discovery Platform Market Drivers
 Table 24. Monoclonal Antibody Discovery Platform Market Challenges
 Table 25. Monoclonal Antibody Discovery Platform Market Restraints
 Table 26. Global Monoclonal Antibody Discovery Platform Revenue by Players (US$ Million), 2021–2026
 Table 27. Global Monoclonal Antibody Discovery Platform Market Share by Players (2021–2026)
 Table 28. Global Top Monoclonal Antibody Discovery Platform Players by Tier (Tier 1, Tier 2, and Tier 3), based on Monoclonal Antibody Discovery Platform Revenue, 2025
 Table 29. Ranking of Global Top Monoclonal Antibody Discovery Platform Companies by Revenue (US$ Million) in 2025
 Table 30. Global 5 Largest Players Market Share by Monoclonal Antibody Discovery Platform Revenue (CR5 and HHI), 2021–2026
 Table 31. Global Key Players of Monoclonal Antibody Discovery Platform, Headquarters and Area Served
 Table 32. Global Key Players of Monoclonal Antibody Discovery Platform, Products and Applications
 Table 33. Global Key Players of Monoclonal Antibody Discovery Platform, Date of General Availability (GA)
 Table 34. Mergers and Acquisitions, Expansion Plans
 Table 35. Global Monoclonal Antibody Discovery Platform Market Size by Discovery Source (US$ Million), 2021–2026
 Table 36. Global Monoclonal Antibody Discovery Platform Revenue Market Share by Discovery Source (2021–2026)
 Table 37. Global Monoclonal Antibody Discovery Platform Forecasted Market Size by Discovery Source (US$ Million), 2027–2032
 Table 38. Global Monoclonal Antibody Discovery Platform Revenue Market Share by Discovery Source (2027–2032)
 Table 39. Global Monoclonal Antibody Discovery Platform Market Size by Application (US$ Million), 2021–2026
 Table 40. Global Monoclonal Antibody Discovery Platform Revenue Market Share by Application (2021–2026)
 Table 41. Global Monoclonal Antibody Discovery Platform Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 42. Global Monoclonal Antibody Discovery Platform Revenue Market Share by Application (2027–2032)
 Table 43. North America Monoclonal Antibody Discovery Platform Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. North America Monoclonal Antibody Discovery Platform Market Size by Country (US$ Million), 2021–2026
 Table 45. North America Monoclonal Antibody Discovery Platform Market Size by Country (US$ Million), 2027–2032
 Table 46. Europe Monoclonal Antibody Discovery Platform Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 47. Europe Monoclonal Antibody Discovery Platform Market Size by Country (US$ Million), 2021–2026
 Table 48. Europe Monoclonal Antibody Discovery Platform Market Size by Country (US$ Million), 2027–2032
 Table 49. Asia-Pacific Monoclonal Antibody Discovery Platform Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 50. Asia-Pacific Monoclonal Antibody Discovery Platform Market Size by Region (US$ Million), 2021–2026
 Table 51. Asia-Pacific Monoclonal Antibody Discovery Platform Market Size by Region (US$ Million), 2027–2032
 Table 52. Latin America Monoclonal Antibody Discovery Platform Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 53. Latin America Monoclonal Antibody Discovery Platform Market Size by Country (US$ Million), 2021–2026
 Table 54. Latin America Monoclonal Antibody Discovery Platform Market Size by Country (US$ Million), 2027–2032
 Table 55. Middle East & Africa Monoclonal Antibody Discovery Platform Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 56. Middle East & Africa Monoclonal Antibody Discovery Platform Market Size by Country (US$ Million), 2021–2026
 Table 57. Middle East & Africa Monoclonal Antibody Discovery Platform Market Size by Country (US$ Million), 2027–2032
 Table 58. AbCellera Biologics Inc. (CA) Company Details
 Table 59. AbCellera Biologics Inc. (CA) Business Overview
 Table 60. AbCellera Biologics Inc. (CA) Monoclonal Antibody Discovery Platform Product
 Table 61. AbCellera Biologics Inc. (CA) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 62. AbCellera Biologics Inc. (CA) Recent Development
 Table 63. Twist Bioscience Corporation (US) Company Details
 Table 64. Twist Bioscience Corporation (US) Business Overview
 Table 65. Twist Bioscience Corporation (US) Monoclonal Antibody Discovery Platform Product
 Table 66. Twist Bioscience Corporation (US) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 67. Twist Bioscience Corporation (US) Recent Development
 Table 68. Adimab LLC (US) Company Details
 Table 69. Adimab LLC (US) Business Overview
 Table 70. Adimab LLC (US) Monoclonal Antibody Discovery Platform Product
 Table 71. Adimab LLC (US) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 72. Adimab LLC (US) Recent Development
 Table 73. Alloy Therapeutics, Inc. (US) Company Details
 Table 74. Alloy Therapeutics, Inc. (US) Business Overview
 Table 75. Alloy Therapeutics, Inc. (US) Monoclonal Antibody Discovery Platform Product
 Table 76. Alloy Therapeutics, Inc. (US) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 77. Alloy Therapeutics, Inc. (US) Recent Development
 Table 78. Biocytogen Pharmaceuticals Co., Ltd. (CN) Company Details
 Table 79. Biocytogen Pharmaceuticals Co., Ltd. (CN) Business Overview
 Table 80. Biocytogen Pharmaceuticals Co., Ltd. (CN) Monoclonal Antibody Discovery Platform Product
 Table 81. Biocytogen Pharmaceuticals Co., Ltd. (CN) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 82. Biocytogen Pharmaceuticals Co., Ltd. (CN) Recent Development
 Table 83. WuXi Biologics (CN) Company Details
 Table 84. WuXi Biologics (CN) Business Overview
 Table 85. WuXi Biologics (CN) Monoclonal Antibody Discovery Platform Product
 Table 86. WuXi Biologics (CN) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 87. WuXi Biologics (CN) Recent Development
 Table 88. Charles River Laboratories International, Inc. (US) Company Details
 Table 89. Charles River Laboratories International, Inc. (US) Business Overview
 Table 90. Charles River Laboratories International, Inc. (US) Monoclonal Antibody Discovery Platform Product
 Table 91. Charles River Laboratories International, Inc. (US) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 92. Charles River Laboratories International, Inc. (US) Recent Development
 Table 93. Sartorius AG (DE) Company Details
 Table 94. Sartorius AG (DE) Business Overview
 Table 95. Sartorius AG (DE) Monoclonal Antibody Discovery Platform Product
 Table 96. Sartorius AG (DE) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 97. Sartorius AG (DE) Recent Development
 Table 98. BioNTech SE (DE) Company Details
 Table 99. BioNTech SE (DE) Business Overview
 Table 100. BioNTech SE (DE) Monoclonal Antibody Discovery Platform Product
 Table 101. BioNTech SE (DE) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 102. BioNTech SE (DE) Recent Development
 Table 103. Grifols, S.A. (ES) Company Details
 Table 104. Grifols, S.A. (ES) Business Overview
 Table 105. Grifols, S.A. (ES) Monoclonal Antibody Discovery Platform Product
 Table 106. Grifols, S.A. (ES) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 107. Grifols, S.A. (ES) Recent Development
 Table 108. Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Company Details
 Table 109. Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Business Overview
 Table 110. Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Monoclonal Antibody Discovery Platform Product
 Table 111. Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 112. Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Recent Development
 Table 113. Harbour BioMed (CN) Company Details
 Table 114. Harbour BioMed (CN) Business Overview
 Table 115. Harbour BioMed (CN) Monoclonal Antibody Discovery Platform Product
 Table 116. Harbour BioMed (CN) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 117. Harbour BioMed (CN) Recent Development
 Table 118. 3SBio Inc. (CN) Company Details
 Table 119. 3SBio Inc. (CN) Business Overview
 Table 120. 3SBio Inc. (CN) Monoclonal Antibody Discovery Platform Product
 Table 121. 3SBio Inc. (CN) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 122. 3SBio Inc. (CN) Recent Development
 Table 123. Lepu Biopharma Co., Ltd. (CN) Company Details
 Table 124. Lepu Biopharma Co., Ltd. (CN) Business Overview
 Table 125. Lepu Biopharma Co., Ltd. (CN) Monoclonal Antibody Discovery Platform Product
 Table 126. Lepu Biopharma Co., Ltd. (CN) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 127. Lepu Biopharma Co., Ltd. (CN) Recent Development
 Table 128. Creative Biolabs (US) Company Details
 Table 129. Creative Biolabs (US) Business Overview
 Table 130. Creative Biolabs (US) Monoclonal Antibody Discovery Platform Product
 Table 131. Creative Biolabs (US) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 132. Creative Biolabs (US) Recent Development
 Table 133. Integral Molecular, Inc. (US) Company Details
 Table 134. Integral Molecular, Inc. (US) Business Overview
 Table 135. Integral Molecular, Inc. (US) Monoclonal Antibody Discovery Platform Product
 Table 136. Integral Molecular, Inc. (US) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 137. Integral Molecular, Inc. (US) Recent Development
 Table 138. AvantGen, Inc. (US) Company Details
 Table 139. AvantGen, Inc. (US) Business Overview
 Table 140. AvantGen, Inc. (US) Monoclonal Antibody Discovery Platform Product
 Table 141. AvantGen, Inc. (US) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 142. AvantGen, Inc. (US) Recent Development
 Table 143. ProteoGenix (FR) Company Details
 Table 144. ProteoGenix (FR) Business Overview
 Table 145. ProteoGenix (FR) Monoclonal Antibody Discovery Platform Product
 Table 146. ProteoGenix (FR) Revenue in Monoclonal Antibody Discovery Platform Business (US$ Million), 2021–2026
 Table 147. ProteoGenix (FR) Recent Development
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Monoclonal Antibody Discovery Platform Picture
 Figure 2. Global Monoclonal Antibody Discovery Platform Market Size Comparison by Discovery Source (US$ Million), 2021–2032
 Figure 3. Global Monoclonal Antibody Discovery Platform Market Share by Discovery Source: 2025 vs 2032
 Figure 4. Hybridoma Features
 Figure 5. Single B Cell Features
 Figure 6. Phage and Yeast Display Features
 Figure 7. Transgenic Animal Features
 Figure 8. AI De Novo Design Features
 Figure 9. Global Monoclonal Antibody Discovery Platform Market Size Comparison by Screening Technology (US$ Million), 2021–2032
 Figure 10. FACS Features
 Figure 11. Microfluidics Features
 Figure 12. Optofluidics Features
 Figure 13. High-Content Screening Features
 Figure 14. Global Monoclonal Antibody Discovery Platform Market Size Comparison by Screening Throughput (US$ Million), 2021–2032
 Figure 15. Below 10,000 cells per run Features
 Figure 16. 10,000–100,000 cells per run Features
 Figure 17. Above 100,000 cells per run Features
 Figure 18. Global Monoclonal Antibody Discovery Platform Market Size by Application (US$ Million), 2021–2032
 Figure 19. Global Monoclonal Antibody Discovery Platform Market Share by Application: 2025 vs 2032
 Figure 20. Therapeutic Antibody Discovery Case Studies
 Figure 21. Diagnostic Antibodies Case Studies
 Figure 22. Research Reagents Case Studies
 Figure 23. Veterinary Biologics Case Studies
 Figure 24. Other Case Studies
 Figure 25. Monoclonal Antibody Discovery Platform Report Years Considered
 Figure 26. Global Monoclonal Antibody Discovery Platform Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 27. Global Monoclonal Antibody Discovery Platform Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 28. Global Monoclonal Antibody Discovery Platform Market Share by Region: 2025 vs 2032
 Figure 29. Global Monoclonal Antibody Discovery Platform Market Share by Players in 2025
 Figure 30. Global Monoclonal Antibody Discovery Platform Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 31. The Top 10 and 5 Players Market Share by Monoclonal Antibody Discovery Platform Revenue in 2025
 Figure 32. North America Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. North America Monoclonal Antibody Discovery Platform Market Share by Country (2021–2032)
 Figure 34. United States Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. Canada Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Europe Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Europe Monoclonal Antibody Discovery Platform Market Share by Country (2021–2032)
 Figure 38. Germany Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. France Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. U.K. Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Italy Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Russia Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Ireland Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Asia-Pacific Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Asia-Pacific Monoclonal Antibody Discovery Platform Market Share by Region (2021–2032)
 Figure 46. China Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. Japan Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. South Korea Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 49. Southeast Asia Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 50. India Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 51. Australia & New Zealand Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 52. Latin America Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 53. Latin America Monoclonal Antibody Discovery Platform Market Share by Country (2021–2032)
 Figure 54. Mexico Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 55. Brazil Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 56. Middle East & Africa Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 57. Middle East & Africa Monoclonal Antibody Discovery Platform Market Share by Country (2021–2032)
 Figure 58. Israel Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 59. Saudi Arabia Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 60. UAE Monoclonal Antibody Discovery Platform Market Size YoY Growth (US$ Million), 2021–2032
 Figure 61. AbCellera Biologics Inc. (CA) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 62. Twist Bioscience Corporation (US) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 63. Adimab LLC (US) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 64. Alloy Therapeutics, Inc. (US) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 65. Biocytogen Pharmaceuticals Co., Ltd. (CN) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 66. WuXi Biologics (CN) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 67. Charles River Laboratories International, Inc. (US) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 68. Sartorius AG (DE) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 69. BioNTech SE (DE) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 70. Grifols, S.A. (ES) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 71. Shanghai Fosun Pharmaceutical Group Co., Ltd. (CN) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 72. Harbour BioMed (CN) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 73. 3SBio Inc. (CN) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 74. Lepu Biopharma Co., Ltd. (CN) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 75. Creative Biolabs (US) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 76. Integral Molecular, Inc. (US) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 77. AvantGen, Inc. (US) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 78. ProteoGenix (FR) Revenue Growth Rate in Monoclonal Antibody Discovery Platform Business (2021–2026)
 Figure 79. Bottom-up and Top-down Approaches for This Report
 Figure 80. Data Triangulation
 Figure 81. Key Executives Interviewed

本レポートが解明する主要な課題

2032年、世界のモノクローナル抗体発見プラットフォーム市場規模はいくらですか？
2032年、世界のモノクローナル抗体発見プラットフォーム市場規模は565です。
2026年、世界のモノクローナル抗体発見プラットフォーム市場規模はいくらですか？
2026年、世界のモノクローナル抗体発見プラットフォーム市場規模は358です。
2026年から2032年までの世界のモノクローナル抗体発見プラットフォーム市場規模の年間複合成長率（CAGR）はどのくらいですか？
2026年から2032年までの世界のモノクローナル抗体発見プラットフォーム市場規模の年間複合成長率（CAGR）は7.9%です。
どの地域が最も高い市場シェアを占めることが予想されていますか？
各地域市場について、市場規模、年間複合成長率（CAGR）、市場需要、産業構造、政策環境、主要企業の展開状況など多角的な観点から詳細な比較分析を行い、各地域の市場特性と競争環境を体系的に整理しました。また、各地域の需要構造、市場成長の原動力、投資環境についても重点的に分析し、企業が重点地域市場を特定したり、グローバル市場戦略や販売戦略を策定する上で貴重な参考情報を提供します。